OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

Research analysts at StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX) in a research note issued on Friday. The firm set a “sell” rating on the stock.

Separately, Needham & Company LLC restated a “buy” rating and issued a $4.25 price target on shares of OncoCyte in a report on Wednesday, November 13th.

OncoCyte Stock Performance

Shares of NASDAQ OCX opened at $2.21 on Friday. The firm’s 50-day moving average price is $2.75 and its 200-day moving average price is $2.92. OncoCyte has a 12-month low of $1.98 and a 12-month high of $3.82.

OncoCyte (NASDAQ:OCX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.54). OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. The business had revenue of $0.12 million for the quarter. During the same period in the previous year, the business earned ($0.57) EPS. Analysts anticipate that OncoCyte will post -2.57 earnings per share for the current fiscal year.

Insider Transactions at OncoCyte

In related news, CFO Andrea S. James purchased 33,670 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was bought at an average cost of $2.97 per share, with a total value of $99,999.90. Following the completion of the acquisition, the chief financial officer now owns 33,670 shares of the company’s stock, valued at $99,999.90. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Broadwood Partners, L.P. acquired 1,315,339 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was purchased at an average cost of $2.95 per share, with a total value of $3,880,250.05. Following the acquisition, the insider now directly owns 6,244,405 shares of the company’s stock, valued at $18,420,994.75. This represents a 26.69 % increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 1,369,009 shares of company stock worth $4,026,050 over the last three months. 1.58% of the stock is currently owned by insiders.

Institutional Investors Weigh In On OncoCyte

A hedge fund recently raised its stake in OncoCyte stock. Geode Capital Management LLC grew its stake in OncoCyte Co. (NASDAQ:OCX) by 12.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 103,980 shares of the company’s stock after acquiring an additional 11,289 shares during the quarter. Geode Capital Management LLC owned about 0.62% of OncoCyte worth $296,000 as of its most recent SEC filing. Institutional investors and hedge funds own 55.35% of the company’s stock.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.